Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
Authors
Patel, M.Lee, J. S.
De Miguel, M. J.
Burns, T.
Gonzalez, A. F.
Kim, T. W.
Krebs, Matthew G
Prenen, H.
Shmueli, E. S.
Desai, J.
Lorusso, P.
Sacher, A.
Choi, Y.
Dharia, N.
Lin, M. T.
Mandlekar, S.
Royer-Joo, S.
Schutzman, J. L.
Garralda, E.
Affiliation
Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute,Sarasota, FLIssue Date
2022
Metadata
Show full item recordCitation
Patel M, Lee JS, De Miguel MJ, Burns T, Gonzalez AF, Kim TW, et al. Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation. Annals of Oncology. 2022 Sep;33(7):S749-S. PubMed PMID: WOS:000866211600453.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.588Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.588Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.588